Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer. [PDF]
, 2013 Data characterizing demographics, treatment patterns, and clinical outcomes in black patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) are limited.
Abidoye, Oyewale O +8 more
core +1 more source
Establishment and characterization of two human breast carcinoma cell lines by spontaneous immortalization: Discordance between Estrogen, Progesterone and HER2/neu receptors of breast carcinoma tissues with derived cell lines [PDF]
, 2012 Background: Breast cancer is one of the most common cancers among women throughout the world. Therefore, established cell lines are widely used as in vitro experimental models in cancer research.Methods: Two continuous human breast cell lines, designated
Akmal, S.N. +6 more
core +1 more source
Nine months versus 12 months of adjuvant trastuzumab for patients with HER2-positive breast cancer [PDF]
Korean Journal of Clinical Oncology, 2018 Purpose This study aimed to compare the results of treatment with adjuvant trastuzumab for 9 months versus 12 months in human epidermal growth factor 2 (HER2)-positive breast cancer patients. The primary endpoint was disease-free survival.
Ashraf Mahmoud El-Enbaby +3 more
doaj +1 more source
[Anti-HER2 vaccines: The HER2 immunotargeting future?].
Pathologie-biologie, 2009 Breast cancer is a widely spread women's disease. In spite of progress in the field of surgery and adjuvant therapies, the risk of breast cancer metastatic relapses remains high especially in those overexpressing HER2. Different studies have shown cellular and/or humoral immune responses against HER2 in patients with HER2-overexpressing tumors.
Ladjemi, Maha-Zohra +3 more
openaire +2 more sources
Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study. [PDF]
, 2012 Limited data exist regarding treatment patterns and outcomes in elderly patients with HER2-positive metastatic breast cancer (MBC). registHER is an observational study of patients (N = 1,001) with HER2-positive MBC diagnosed within 6 months of enrollment
Brufsky, Adam M +9 more
core +1 more source
Radiology and Oncology, 2019 Colorectal cancer is a successful model of genetic biomarker development in oncology. Currently, several predictive or prognostic genetic alterations have been identified and are used in clinical practice.
Afrăsânie Vlad-Adrian +7 more
doaj +1 more source
Cardiac Safety of Trastuzumab on 185 Patients with HER2 Positive Breast Cancer
Zhongliu Fangzhi Yanjiu, 2018 Objective To analyze the cardiac safety of trastuzumab on HER2 positive breast cancer patients. Methods Trastuzumab was administrated every three weeks in 185 patients with HER2 positive breast cancer.
MENG Wenjing +3 more
doaj +1 more source
International Journal of Nanomedicine, 2023 Wenbin Cai,1,2,* Wei Lv,1,3,* Li Meng,2 Yunyou Duan,1 Li Zhang1 1Department of Ultrasound Medical, Tangdu Hospital, the Fourth Military Medical University, Xi’an, People’s Republic of China; 2Department of Ultrasound Diagnostics, General Hospital
Cai W, Lv W, Meng L, Duan Y, Zhang L
doaj
Cancer Research, Statistics, and Treatment, 2020 Introduction: Majority of the patients in low-to-middle income countries (LMICs) have no access to adjuvant trastuzumab due to financial constraints. Short-course (9 weeks) schedule of trastuzumab is a feasible alternative in this setting.
Avaronnan Manuprasad +5 more
doaj +1 more source
Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer [PDF]
, 2017 SRC tyrosine kinase is frequently overexpressed and activated in late-stage, poor prognosis ovarian tumours, and preclinical studies have supported the use of targeted SRC inhibitors in the treatment of this disease.
El-Helali, Aya +6 more
core +2 more sources